Keep pulling the thread on Chen Hao.
Existing gene silencing medicines on the market have a clinical trial success rate of approximately 70%, compared to a 95% failure rate for many traditional medicines.
Avidity Bio was recently acquired for $12 billion for its technology that delivers gene silencing therapies to skeletal muscle.
Over the last five years, the success rate for building a drug delivery system at Gnosis Bio has improved from one in a trillion to a 10-30% success rate due to its AI platform.
Gnosis Bio's platform is approximately 80% cheaper and three times faster for developing targeted gene silencing medicines compared to traditional methods.
In China, a clinical trial can be initiated with only university approval, making it significantly faster and cheaper to demonstrate drug safety and efficacy compared to the United States.
Jake Rubins predicts the American biotech industry will decline unless the FDA reforms its drug development requirements to compete with China's efficiency.
China's government has made biotech a strategic priority and is investing significantly more in scientific research and instrumentation than the United States.
Jim Martineau predicts that within five years, the term 'undruggable' will be eliminated from the pharmaceutical lexicon due to AI's ability to design molecules for any target.
Jake Rubins predicts that within the next five to 10 years, it will be possible to receive a preventative injection that vaccinates a person against developing Alzheimer's, cardiovascular disease, and obesity.
Traditional CRISPR Cas9 systems can induce a DNA damage response and chromosome rearrangement when they cut or edit DNA.
Algen's proprietary CRISPR technology regulates gene expression up and down without cutting or editing DNA, avoiding the DNA damage associated with traditional methods.
Algen recently signed a large-scale partnership with AstraZeneca to utilize its platform for new biology discovery.